KRYS — Krystal Biotech Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $268.04
- 30-Day Move
- +12.4%
- Market Cap
- $7.6B
- Shares Outstanding
- 29,230,000
- P/E Ratio
- 37.24
- P/B Ratio
- 5.86
Krystal Biotech Inc
A read-only Alphactor snapshot forKrystal Biotech Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$268.04
30-Day Move
+12.4%
Market Cap
$7.6B
Shares Outstanding
29,230,000
P/E Ratio
37.24
P/B Ratio
5.86
$268.04
+12.4%last 90 delayed daily bars
90D High
$298.30
90D Low
$231.69
Avg Volume
288,623
Gross margin is running at 94.1%, which gives a quick read on operating quality before you open the full model.
Net margin is 52.6%, useful for comparing KRYS against peers in Biotechnology.
KRYS is up 12.4% over the last 30 trading days shown on this page.
Latest operating income is $44M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$103.46
Rule of 40
82.5%
Latest Close
$268.04
30-Day Move
+12.4%
Market Cap
$7.6B
Shares Outstanding
29,230,000
P/E Ratio
37.24
P/B Ratio
5.86
ROE
16.8%
ROA
15.4%
Gross Margin
94.1%
Operating Margin
41.4%
Net Margin
52.6%
Debt / Equity
0
Current Ratio
9.95
Latest Revenue
$107M
Revenue
$107M
Gross Profit
$101M
Operating Income
$44M
Net Income
$51M
Gross Margin
9408.0%
Net Margin
5264.0%
Current Ratio
9.95
Debt / Equity
0.00
Fair Value
$103.46
Upside / Downside
-61.4%
Signal
Overvalued
Implied Growth
14.8%
DCF
$123.70
EV/Rev
$83.22
Growth Assumption
5.0%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$189M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
41.61
Safe
Piotroski
7
Strong (7-9)
Cash Conversion
0.98x
Rule of 40
82.5%
Elite
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-120M | $-140M | $-154M |
| 2023-12-31 | $51M | $-97M | $11M | $-101M |
| 2024-12-31 | $291M | $103M | $89M | $119M |
| 2025-12-31 | $389M | $161M | $205M | $189M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
T. Rowe Price
Filed 2025-08-14
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$1.1B
+0.2%
BlackRock
Filed 2024-08-13
$725M
--
Vanguard Group
Filed 2026-01-29
$685M
-0.5%
Geode Capital Management
Filed 2026-02-09
$151M
+0.1%
Citadel Advisors
Filed 2025-11-14
$112M
--
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.